Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1 ...

ST. MARYS, W.Va. (WTAP) - The 30th annual Battle Against Cystic Fibrosis football game will be held this Friday to raise ...

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Oral presentation on outcomes following ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy. Details of the oral presentation are as follows: Abstract Title: Stabilizers of CFTR NBD1 synergize with ...

will be presented at the European Cystic Fibrosis Society’s conference in Milan from June 4-7, 2025. The presentation will explore how these NBD1 stabilizers can synergize with CFTR modulators ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive ...